Biogen appoints Michael McDonnell as Chief Financial Officer and Executive Vice President

pharmafile | July 23, 2020 | Appointment | Business Services  

Biogen have announced that they have appointed Michael McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020.

McDonnell makes a switch from IQVIA where he is both Vice President and Chief Financial Officer. He succeeds Jeffrey Capello in both positions, who has held them since 2017. Capello will remain at the company until September to assist with the transition.

Michel Vounatsos, Chief Executive Officer, said: “I am thrilled to welcome Mike to Biogen at this exciting time when we have so many potential breakthrough therapies in our pipeline. Mike’s background and track record of accomplishments – including his extensive expertise in value-creating, strategic financial considerations – make him particularly well suited for Biogen at this moment in our history.

“I would like to thank Jeff for his many contributions to Biogen and we are pleased that Jeff will be staying on for a brief period to ensure a seamless transition. We wish him well.”

Before joining IQVIA, McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat from November 2008 to December 2015. He also had roles at MCG Capital Corporation, Echostar Communications and PricewaterhouseCoopers LLP. He has a bachelor of science in accounting from Georgetown University.

Commenting on his appointment, McDonnell said: “As a business partner, I have long admired the strength of Biogen’s pipeline and its commitment to combatting neurological diseases. I am excited by the multiple potential growth opportunities and the prospect of building on Biogen’s established position as a leader in neuroscience. I look forward to joining Biogen and working with my future colleagues to drive sustained performance and growth.”

Related Content

No items found

Latest content